Insulin-like growth factors (IGF-I and -II): new actors in the development of non-alcoholic fatty liver disease

References

• Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9(3):152-61
   PubMed Web of Science ®Google Scholar
• Hazlehurst JM, Tomlinson JW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013;169(2):R27-37
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Hamasaki K, Ishikawa H, et al. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003;52(6):914
   Google Scholar
• Fukuda I, Hizuka N, Yasumoto K, et al. Metabolic co-morbidities revealed in patients with childhood-onset adult GH deficiency after cessation of GH replacement therapy for short stature. Endocr J 2008;55(6):977-84
   Google Scholar
• Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 2012;167(1):67-74
   PubMed Web of Science ®Google Scholar
• Bredella MA, Gerweck AV, Lin E, et al. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. J Clin Endocrinol Metab 2013;98(9):3864-72
   Google Scholar
• Nishizawa H, Takahashi M, Fukuoka H, et al. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun 2012;423(2):295-300
   PubMed Web of Science ®Google Scholar
• Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. Endocr J 2012;59(11):955-62
   Google Scholar
• Donaghy A, Ross R, Wicks C, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology 1997;113(5):1617-22
   PubMed Web of Science ®Google Scholar
• Mallea-Gil MS, Ballarino MC, Spiraquis A, et al. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam 2012;42(1):20-6
   Google Scholar
• Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007;17(4):493-503
   Google Scholar
• Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 2007;1(2):287-94
   PubMed Web of Science ®Google Scholar
• Yakar S, Liu JL, Fernandez AM, et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50(5):1110-18
   PubMed Web of Science ®Google Scholar
• Colak Y, Senates E, Ozturk O, et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 2012;24(3):255-61
   PubMed Web of Science ®Google Scholar
• Sanz S, Pucilowska JB, Liu S, et al. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005;54(1):134-41
   Google Scholar
• Sobrevals L, Rodriguez C, Romero-Trevejo JL, et al. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010;51(3):912-21
   PubMed Web of Science ®Google Scholar
• Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005;43(4):630-6
   Google Scholar
• Hao CN, Geng YJ, Li F, et al. Insulin-like growth factor-1 receptor activation prevents hydrogen peroxide-induced oxidative stress, mitochondrial dysfunction and apoptosis. Apoptosis 2011;16(11):1118-27
   Google Scholar
• Puche JE, Garcia-Fernandez M, Muntane J, et al. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 2008;149(5):2620-7
   Google Scholar
• Savastano S, Di Somma C, Pizza G, et al. Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J Transl Med 2011;9:136
   PubMed Web of Science ®Google Scholar
• Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013;98(2):E304-8
   PubMed Web of Science ®Google Scholar
• Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437(7059):759-63
   PubMed Web of Science ®Google Scholar
• Cianfarani S. Insulin-like growth factor-II: new roles for an old actor. Front Endocrinol (Lausanne) 2012;3:118
   Google Scholar
• Rehem RN, El-Shikh WM. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 2011;58(107-108):949-54
   Google Scholar
• Cianfarani S, Inzaghi E, Alisi A, et al. Insulin-like growth factor–I and –II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. J Pediatr 2014; In press
   Google Scholar